<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2-Methylbutyryl-CoA Dehydrogenase Deficiency - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>2-Methylbutyryl-CoA Dehydrogenase Deficiency</span>
        </nav>

        <header class="page-header">
            <h1>2-Methylbutyryl-CoA Dehydrogenase Deficiency</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0012392" target="_blank">
                        MONDO:0012392
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Organic Acidemia</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                2-Methylbutyryl-CoA dehydrogenase deficiency (SBCADD) is an autosomal recessive inborn error of L-isoleucine metabolism caused by biallelic pathogenic variants in the ACADSB gene encoding short/branched-chain acyl-CoA dehydrogenase (SBCAD). The metabolic block in the proximal isoleucine oxidation pathway leads to accumulation of diagnostic metabolites including elevated C5-acylcarnitine (2-methylbutyrylcarnitine) in blood and 2-methylbutyrylglycine (2-MBG) in urine. Most individuals identified through newborn screening remain asymptomatic, but approximately 10% of reported patients develop clinical manifestations including seizures, developmental delay, hypotonia, and failure to thrive. The condition is particularly prevalent in the Hmong population due to a founder mutation (c.1165A&gt;G). Carnitine supplementation and avoidance of catabolic stress are the mainstays of management.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">ACADSB molecular function deficiency</div>
                
                <div class="item-desc">Biallelic ACADSB pathogenic variants reduce short/branched-chain acyl-CoA dehydrogenase catalytic activity in mitochondria.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        ACADSB
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        catalytic activity
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0003824" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"2-methylbutyryl-CoA dehydrogenase deficiency, also known as short/branched-chain acyl-CoA dehydrogenase (SBCAD) deficiency, is a recently described autosomal recessive disorder of L-isoleucine metabolism.
"</div>
                
                
                <div class="evidence-explanation">Directly supports primary SBCAD/ACADSB molecular dysfunction in this disorder.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired isoleucine catabolism via SBCAD loss-of-function</div>
                
                <div class="item-desc">Loss-of-function variants reduce SBCAD enzyme activity and stability, blocking this catabolic step and causing accumulation of upstream metabolites that are diverted to measurable conjugates including C5-acylcarnitine (blood) and 2-methylbutyrylglycine (urine).
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        isoleucine catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006548" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        branched-chain amino acid catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0009083" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15615815" target="_blank">PMID:15615815</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Isolated excretion of 2-methylbutyrylglycine (2-MBG) is the hallmark of short/branched-chain acyl-CoA dehydrogenase deficiency (SBCADD), a recently identified defect in the proximal pathway of L-isoleucine oxidation.
"</div>
                
                
                <div class="evidence-explanation">Confirms that SBCADD is a defect in the proximal pathway of L-isoleucine oxidation with 2-MBG as hallmark metabolite.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Metabolic rerouting via the R-pathway of isoleucine oxidation</div>
                
                <div class="item-desc">The metabolic block in the S-pathway of isoleucine oxidation leads to increased flux through the normally minor R-pathway, producing 2-ethylhydracrylic acid (2-EHA) as a prominent urinary marker. This R-pathway flux may function as a compensatory safety valve that mitigates severity in many individuals, explaining the largely benign phenotype observed in most SBCADD patients.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        isoleucine catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006548" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15615815" target="_blank">PMID:15615815</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increased flux through the R-pathway may act as a safety valve for overflow of accumulating S-pathway metabolites and thereby mitigate the severity of SBCADD.
"</div>
                
                
                <div class="evidence-explanation">Directly supports the hypothesis that R-pathway flux compensates for the S-pathway block and explains the mild phenotype.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15615815" target="_blank">PMID:15615815</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Approximately 40-46% of total 2-methylbutyric acid conjugates were in the form of the R-isomer, indicating significant metabolism via the R-pathway.
"</div>
                
                
                <div class="evidence-explanation">Quantifies the significant contribution of R-pathway metabolism in SBCADD patients.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Stress-sensitive metabolic decompensation</div>
                
                <div class="item-desc">Overlapping substrate specificity among ACAD family enzymes may compensate for SBCAD deficiency under normal conditions. During catabolic stress (infection, fasting), this compensatory capacity may be exceeded, leading to metabolic decompensation in a minority of patients. This stress-sensitive model explains why most patients remain asymptomatic but a small fraction develop clinical disease.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to starvation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042594" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Catabolic situations can precipitate acute metabolic decompensation.
"</div>
                
                
                <div class="evidence-explanation">Directly supports that catabolic stress triggers decompensation in SBCADD.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">ACAD substrate promiscuity and compensatory enzymology</div>
                
                <div class="item-desc">ACAD family enzymes display significant substrate promiscuity. In HEK-293 cell models, ACADSB knockout causes marked increases in C5-carnitine and substantial decreases in C3-carnitine, demonstrating that SBCAD activity influences short-chain acyl-CoA and acylcarnitine pools beyond a single metabolite. This promiscuity partially explains why complete SBCAD loss-of-function has limited clinical consequences in most individuals.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        fatty acid beta-oxidation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006635" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37309295" target="_blank">PMID:37309295</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Deficiencies of these acyl-CoA dehydrogenase (ACAD) enzymes are considered biochemical abnormalities with limited or no clinical consequences.
"</div>
                
                
                <div class="evidence-explanation">Expert consensus statement from 2023 JIMD paper characterizing SBCAD deficiency as largely a biochemical abnormality.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    ACADSB_molecular_function_deficiency[&#34;ACADSB molecular function deficiency&#34;]
    Stress_sensitive_metabolic_decompensation[&#34;Stress-sensitive metabolic decompensation&#34;]
    Metabolic_rerouting_via_the_R_pathway_of_isoleucine_oxidation[&#34;Metabolic rerouting via the R-pathway of isoleucine oxidation&#34;]
    Impaired_isoleucine_catabolism_via_SBCAD_loss_of_function[&#34;Impaired isoleucine catabolism via SBCAD loss-of-function&#34;]

    ACADSB_molecular_function_deficiency --&gt; Impaired_isoleucine_catabolism_via_SBCAD_loss_of_function
    Impaired_isoleucine_catabolism_via_SBCAD_loss_of_function --&gt; Metabolic_rerouting_via_the_R_pathway_of_isoleucine_oxidation
    Metabolic_rerouting_via_the_R_pathway_of_isoleucine_oxidation --&gt; Stress_sensitive_metabolic_decompensation

    style ACADSB_molecular_function_deficiency fill:#dbeafe
    style Stress_sensitive_metabolic_decompensation fill:#dbeafe
    style Metabolic_rerouting_via_the_R_pathway_of_isoleucine_oxidation fill:#dbeafe
    style Impaired_isoleucine_catabolism_via_SBCAD_loss_of_function fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Head and Neck<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Nervous System<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Growth<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Other<span class="pill-count">(4)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Head and Neck
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Microcephaly
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000252" target="_blank">
                                Microcephaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000252)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"On longitudinal follow-up, epilepsy, developmental delay, microcephaly, and autism can develop.
"</div>
                
                
                <div class="evidence-explanation">Microcephaly listed as a feature that can develop on longitudinal follow-up.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Muscular hypotonia
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                                Hypotonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001252)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Except for 1 patient who developed mild muscle hypotonia, all patients remain asymptomatic at ages ranging from 3 to 14 months of age.
"</div>
                
                
                <div class="evidence-explanation">Reports mild muscle hypotonia in one of the newborn-screening- identified Hmong patients.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure to thrive.
"</div>
                
                
                <div class="evidence-explanation">Hypotonia listed among presenting features in the literature review.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Developmental delay
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001263" target="_blank">
                                Global developmental delay
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001263)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"One patient developed athetoid cerebral palsy, and another had severe motor developmental delay with muscle atrophy.
"</div>
                
                
                <div class="evidence-explanation">Two of the earliest described patients showed motor developmental delay or cerebral palsy.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure to thrive.
"</div>
                
                
                <div class="evidence-explanation">Literature review confirms developmental delay as a recognized phenotype of symptomatic SBCADD.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Seizures
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                                Seizure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001250)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure to thrive.
"</div>
                
                
                <div class="evidence-explanation">Seizures listed as a recognized presenting feature of symptomatic SBCADD.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"On longitudinal follow-up, epilepsy, developmental delay, microcephaly, and autism can develop.
"</div>
                
                
                <div class="evidence-explanation">Epilepsy can develop on longitudinal follow-up in symptomatic cases.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Autism
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000717" target="_blank">
                                Autism
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000717)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"On longitudinal follow-up, epilepsy, developmental delay, microcephaly, and autism can develop.
"</div>
                
                
                <div class="evidence-explanation">Autism listed among features that can develop on longitudinal follow-up in SBCADD.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dyskinetic cerebral palsy
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001266" target="_blank">
                                Choreoathetosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001266)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"One patient developed athetoid cerebral palsy, and another had severe motor developmental delay with muscle atrophy.
"</div>
                
                
                <div class="evidence-explanation">Directly reports athetoid cerebral palsy in one of the first described SBCADD patients.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Failure to thrive
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001508" target="_blank">
                                Failure to thrive
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001508)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure to thrive.
"</div>
                
                
                <div class="evidence-explanation">Failure to thrive listed among presenting features in the literature review of 162 patients.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Skeletal muscle atrophy
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003202" target="_blank">
                                Skeletal muscle atrophy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003202)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"One patient developed athetoid cerebral palsy, and another had severe motor developmental delay with muscle atrophy.
"</div>
                
                
                <div class="evidence-explanation">Directly reports muscle atrophy in an early SBCADD patient.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Elevated C5-acylcarnitine on newborn screening
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0045045" target="_blank">
                                Elevated circulating acylcarnitine concentration
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0045045)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        2-Methylbutyrylglycinuria
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001992" target="_blank">
                                Organic aciduria
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001992)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increased urinary excretion of 2-methylbutyrylglycine (2MBG) is the hallmark of SBCAD deficiency.
"</div>
                
                
                <div class="evidence-explanation">Directly identifies elevated urinary 2-MBG as the hallmark of SBCADD.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31555323" target="_blank">PMID:31555323</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"All patients who underwent urinary organic acid analysis showed elevation of 2-methylburtyrylglycine in urine.
"</div>
                
                
                <div class="evidence-explanation">Confirms universal 2-MBG elevation in confirmed SBCADD patients.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Largely asymptomatic course
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Many individuals are identified through newborn screening and remain well without treatment on long-term follow-up.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Based on our experience and the literature review (162 patients), SBCAD deficiency is symptomatic in about 10% of reported patients.
"</div>
                
                
                <div class="evidence-explanation">Quantifies the largely asymptomatic nature of SBCADD in the largest literature review.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20547083" target="_blank">PMID:20547083</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Our patients have been well without treatment and call for careful follow-up studies to learn the true clinical impact of this disorder.
"</div>
                
                
                <div class="evidence-explanation">Confirms asymptomatic status of non-Hmong patients identified by newborn screening.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ACADSB pathogenic variants
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal recessive</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20547083" target="_blank">PMID:20547083</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Short/branched chain acyl-CoA dehydrogenase (SBCAD) deficiency, also known as 2-methylbutyryl-CoA dehydrogenase deficiency, is a recently described autosomal recessive disorder of isoleucine metabolism. Most patients reported thus far have originated from a founder mutation in the Hmong Chinese..."</div>
                
                
                <div class="evidence-explanation">Confirms the genetic basis and founder mutation background of SBCADD.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16950638" target="_blank">PMID:16950638</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"Confirmation of diagnosis is therefore advisable by specific enzyme assay and/or mutation analysis of the ACAT1 (beta-KT), ACADSB (SBCAD) or HADH2 (MHBD) genes.
"</div>
                
                
                <div class="evidence-explanation">Confirms ACADSB as the gene for molecular diagnosis of SBCADD.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Carnitine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">L-carnitine supplementation (typically 50-100 mg/kg/day) is used to support conjugation and excretion of accumulating acyl-CoA intermediates as acylcarnitine species. Carnitine supplementation is one of the most consistently recommended interventions in SBCADD management.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine supplementation and valproate avoidance appear to be indicated.
"</div>
                
                
                <div class="evidence-explanation">Directly recommends carnitine supplementation as an indicated treatment for SBCADD.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Longitudinal biochemical monitoring of the two patients while on treatment with carnitine (100 mg/kg/day) was provided.
"</div>
                
                
                <div class="evidence-explanation">Reports specific carnitine dosing of 100 mg/kg/day with biochemical monitoring.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Catabolic stress avoidance and emergency protocol
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Prevention of metabolic decompensation through avoidance of prolonged fasting, protein overload, and provision of an emergency protocol for management of intercurrent febrile illnesses and acute catabolic episodes.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Providing an emergency protocol for the management of acute catabolic episodes seems reasonable in asymptomatic patients with SBCAD deficiency.
"</div>
                
                
                <div class="evidence-explanation">Directly supports emergency protocol provision for catabolic stress management.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Catabolic situations can precipitate acute metabolic decompensation.
"</div>
                
                
                <div class="evidence-explanation">Supports the rationale for catabolic stress avoidance.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Dietary management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Dietary intervention in SBCADD is controversial. Early-identified cases historically received low-protein diets with fasting avoidance, but the indication for disruptive dietary manipulations in asymptomatic newborn-screening-identified infants is questionable. Current practice favors maintaining a normal diet with vigilance during intercurrent illness rather than protein restriction.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Dietary treatment was initiated in the neonatal period. Except for 1 patient who developed mild muscle hypotonia, all patients remain asymptomatic at ages ranging from 3 to 14 months of age.
"</div>
                
                
                <div class="evidence-explanation">Reports early dietary treatment in newborn-screening-identified Hmong patients with good short-term outcomes.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The continued efficacy of long-term dietary therapy instituted presymptomatically remains to be established.
"</div>
                
                
                <div class="evidence-explanation">Notes that long-term efficacy of presymptomatic dietary treatment is unproven.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Valproate avoidance
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Valproate should be avoided in SBCADD patients because valproyl-CoA can serve as a substrate of SBCAD, and valproate administration may exacerbate the metabolic block.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine supplementation and valproate avoidance appear to be indicated.
"</div>
                
                
                <div class="evidence-explanation">Directly recommends valproate avoidance as an indicated measure in SBCADD management.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Newborn screening via tandem mass spectrometry
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000124" target="_blank">
                            MAXO:0000124
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">SBCADD is detectable by expanded newborn screening using tandem mass spectrometry. Elevated C5-acylcarnitine triggers follow-up testing including urine organic acids and acylglycine analysis, followed by molecular confirmation of ACADSB variants.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"These cases suggest that SBCAD deficiency is another inborn error of metabolism detectable by newborn screening using tandem mass spectrometry.
"</div>
                
                
                <div class="evidence-explanation">Establishes that SBCADD is detectable by tandem MS newborn screening.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling for affected families regarding autosomal recessive inheritance, carrier testing, recurrence risk (25%), and options for prenatal diagnosis. Particularly relevant in the Hmong community where the carrier frequency exceeds 20%.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12837870" target="_blank">PMID:12837870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"A sibling of the first patient is asymptomatic after prenatal diagnosis and early treatment.
"</div>
                
                
                <div class="evidence-explanation">Demonstrates prenatal diagnosis has been applied in SBCADD families, supporting the role of genetic counseling.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Longitudinal monitoring
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Long-term clinical and biochemical follow-up is recommended for all individuals with confirmed SBCADD, even those who are asymptomatic, to monitor for late-onset neurological or developmental complications and to assess the natural history of the condition.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Longitudinal follow-up is recommended.
"</div>
                
                
                <div class="evidence-explanation">Directly recommends longitudinal follow-up in SBCADD.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    C5-acylcarnitine (2-methylbutyrylcarnitine)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated C5-acylcarnitine in blood is the primary newborn screening marker for SBCADD. C5 is isobaric with isovalerylcarnitine on standard tandem mass spectrometry, requiring second-tier testing to distinguish SBCADD from isovaleric acidemia.
</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    2-Methylbutyrylglycine (2-MBG) in urine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated urinary 2-methylbutyrylglycine is the diagnostic hallmark of SBCADD. Detection of 2-MBG by urine organic acid analysis or acylglycine profiling confirms the diagnosis after elevated C5 is found on newborn screening.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30730842" target="_blank">PMID:30730842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increased urinary excretion of 2-methylbutyrylglycine (2MBG) is the hallmark of SBCAD deficiency.
"</div>
                
                
                <div class="evidence-explanation">Confirms 2-MBG elevation as the hallmark in the 2019 literature review.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    2-Ethylhydracrylic acid (2-EHA) in urine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: 2-Ethylhydracrylic acid is a urinary organic acid marker of SBCADD, produced by increased flux through the R-pathway of isoleucine oxidation. The 2-EHA peak often exceeds the 2-MBG peak on organic acid analysis and may facilitate diagnosis.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15615815" target="_blank">PMID:15615815</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In multiple urine samples, organic acid analysis revealed a prominent 2-EHA peak usually exceeding the size of the 2-MBG peak.
"</div>
                
                
                <div class="evidence-explanation">Demonstrates that 2-EHA is a prominent urinary marker in SBCADD, often exceeding 2-MBG levels.
</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15615815" target="_blank">PMID:15615815</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Awareness of 2-ethylhydracrylic aciduria as a diagnostic marker could lead to increased detection of SBCADD and improved definition of its clinical phenotype.
"</div>
                
                
                <div class="evidence-explanation">Supports diagnostic utility of 2-EHA for SBCADD detection.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    C3-carnitine (propionylcarnitine) in ACADSB knockout cells
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: In cell models of SBCAD deficiency, C3-carnitine is substantially decreased, reflecting the broader impact of SBCAD on mitochondrial acyl-CoA handling beyond the direct isoleucine pathway metabolites. This is an in vitro observation and not a standard clinical biomarker.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37309295" target="_blank">PMID:37309295</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"deletion of ACADSB in HEK-293 cells led to an equally strong decrease in C3-carnitine when compared to wild-type cells.
"</div>
                
                
                <div class="evidence-explanation">ACADSB knockout in HEK-293 cells causes substantial C3-carnitine decrease, demonstrating broader metabolic impact.
</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: 2-Methylbutyryl-CoA Dehydrogenase Deficiency
category: Mendelian
creation_date: &#39;2026-02-23T00:00:00Z&#39;
updated_date: &#39;2026-02-28T01:20:00Z&#39;
synonyms:
- Short/branched-chain acyl-CoA dehydrogenase deficiency
- SBCADD
- SBCAD deficiency
- 2-methylbutyrylglycinuria
- 2-MBCDD
- 2-methylbutyryl-CoA dehydrogenase deficiency
description: &#39;2-Methylbutyryl-CoA dehydrogenase deficiency (SBCADD) is an autosomal recessive inborn error of L-isoleucine
  metabolism caused by biallelic pathogenic variants in the ACADSB gene encoding short/branched-chain acyl-CoA dehydrogenase
  (SBCAD). The metabolic block in the proximal isoleucine oxidation pathway leads to accumulation of diagnostic metabolites
  including elevated C5-acylcarnitine (2-methylbutyrylcarnitine) in blood and 2-methylbutyrylglycine (2-MBG) in urine. Most
  individuals identified through newborn screening remain asymptomatic, but approximately 10% of reported patients develop
  clinical manifestations including seizures, developmental delay, hypotonia, and failure to thrive. The condition is particularly
  prevalent in the Hmong population due to a founder mutation (c.1165A&gt;G). Carnitine supplementation and avoidance of catabolic
  stress are the mainstays of management.

  &#39;
disease_term:
  preferred_term: 2-methylbutyryl-CoA dehydrogenase deficiency
  term:
    id: MONDO:0012392
    label: 2-methylbutyryl-CoA dehydrogenase deficiency
parents:
- Organic Acidemia
- Inborn Error of Metabolism
prevalence:
- population: Hmong (Wisconsin, USA)
  percentage: 1.3
  notes: &#39;Prevalence of homozygosity for the founder c.1165A&gt;G mutation is approximately 1.3% (1 in 77) in the Hmong population,
    with a carrier frequency of 21.8%.

    &#39;
- population: Newborns, Huaihua, China
  notes: &#39;Incidence 1 in 7,137 in a 206,977-newborn screening cohort in Huaihua, China (2015-2021), the most common IEM in
    that cohort.

    &#39;
  evidence:
  - reference: PMID:38784038
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;The two most common disorders were 2-methylbutyryl glycinuria (1:7,137) and phenylalanine hydroxylase deficiency
      (1:22,997).

      &#39;
    explanation: &#39;Reports SBCADD incidence of 1:7,137 in the Huaihua NBS cohort.

      &#39;
- population: Newborns, Quanzhou, China
  notes: &#39;Estimated incidence of 1 in 30,379 based on NBS ascertainment in Quanzhou, China.

    &#39;
  evidence:
  - reference: PMID:31555323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;The estimated incidence of SBCADD was 1 in 30,379 in Quanzhou, China.

      &#39;
    explanation: &#39;Provides incidence estimate from the Quanzhou NBS cohort.

      &#39;
progression:
- phase: Neonatal/early detection
  notes: &#39;Most individuals are identified through newborn screening via elevated C5-acylcarnitine. The majority remain asymptomatic
    throughout life. Approximately 10% develop symptoms, typically in the neonatal period or during intercurrent illness.
    Compensation via alternative ACAD enzymes and the R-pathway of isoleucine oxidation may mask biochemical consequences
    at baseline, but this compensation can fail during metabolic stress (infection, fasting), leading to sporadic decompensation
    in susceptible individuals.

    &#39;
pathophysiology:
- name: ACADSB molecular function deficiency
  description: &#39;Biallelic ACADSB pathogenic variants reduce short/branched-chain
    acyl-CoA dehydrogenase catalytic activity in mitochondria.

    &#39;
  genes:
  - preferred_term: ACADSB
  biological_processes:
  - preferred_term: catalytic activity
    term:
      id: GO:0003824
      label: catalytic activity
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:12837870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;2-methylbutyryl-CoA dehydrogenase deficiency, also known as short/branched-chain acyl-CoA dehydrogenase (SBCAD)
      deficiency, is a recently described autosomal recessive disorder of L-isoleucine metabolism.

      &#39;
    explanation: &#39;Directly supports primary SBCAD/ACADSB molecular dysfunction in this disorder.

      &#39;
  downstream:
  - target: Impaired isoleucine catabolism via SBCAD loss-of-function
    description: Reduced SBCAD function blocks proximal S-pathway oxidation of 2-methylbutyryl-CoA.
- name: Impaired isoleucine catabolism via SBCAD loss-of-function
  description: &#39;Loss-of-function variants reduce SBCAD enzyme activity and stability,
    blocking this catabolic step and causing accumulation of upstream metabolites
    that are diverted to measurable conjugates including C5-acylcarnitine (blood)
    and 2-methylbutyrylglycine (urine).

    &#39;
  biological_processes:
  - preferred_term: isoleucine catabolic process
    term:
      id: GO:0006548
      label: isoleucine catabolic process
  - preferred_term: branched-chain amino acid catabolic process
    term:
      id: GO:0009083
      label: branched-chain amino acid catabolic process
  evidence:
  - reference: PMID:15615815
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Isolated excretion of 2-methylbutyrylglycine (2-MBG) is the hallmark of short/branched-chain acyl-CoA dehydrogenase
      deficiency (SBCADD), a recently identified defect in the proximal pathway of L-isoleucine oxidation.

      &#39;
    explanation: &#39;Confirms that SBCADD is a defect in the proximal pathway of L-isoleucine oxidation with 2-MBG as hallmark
      metabolite.

      &#39;
  downstream:
  - target: Metabolic rerouting via the R-pathway of isoleucine oxidation
- name: Metabolic rerouting via the R-pathway of isoleucine oxidation
  description: &#39;The metabolic block in the S-pathway of isoleucine oxidation leads to increased flux through the normally
    minor R-pathway, producing 2-ethylhydracrylic acid (2-EHA) as a prominent urinary marker. This R-pathway flux may function
    as a compensatory safety valve that mitigates severity in many individuals, explaining the largely benign phenotype observed
    in most SBCADD patients.

    &#39;
  biological_processes:
  - preferred_term: isoleucine catabolic process
    term:
      id: GO:0006548
      label: isoleucine catabolic process
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:15615815
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Increased flux through the R-pathway may act as a safety valve for overflow of accumulating S-pathway metabolites
      and thereby mitigate the severity of SBCADD.

      &#39;
    explanation: &#39;Directly supports the hypothesis that R-pathway flux compensates for the S-pathway block and explains the
      mild phenotype.

      &#39;
  - reference: PMID:15615815
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Approximately 40-46% of total 2-methylbutyric acid conjugates were in the form of the R-isomer, indicating significant
      metabolism via the R-pathway.

      &#39;
    explanation: &#39;Quantifies the significant contribution of R-pathway metabolism in SBCADD patients.

      &#39;
  downstream:
  - target: Stress-sensitive metabolic decompensation
- name: Stress-sensitive metabolic decompensation
  description: &#39;Overlapping substrate specificity among ACAD family enzymes may compensate for SBCAD deficiency under normal
    conditions. During catabolic stress (infection, fasting), this compensatory capacity may be exceeded, leading to metabolic
    decompensation in a minority of patients. This stress-sensitive model explains why most patients remain asymptomatic but
    a small fraction develop clinical disease.

    &#39;
  biological_processes:
  - preferred_term: response to starvation
    term:
      id: GO:0042594
      label: response to starvation
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Catabolic situations can precipitate acute metabolic decompensation.

      &#39;
    explanation: &#39;Directly supports that catabolic stress triggers decompensation in SBCADD.

      &#39;
- name: ACAD substrate promiscuity and compensatory enzymology
  description: &#39;ACAD family enzymes display significant substrate promiscuity. In HEK-293 cell models, ACADSB knockout causes
    marked increases in C5-carnitine and substantial decreases in C3-carnitine, demonstrating that SBCAD activity influences
    short-chain acyl-CoA and acylcarnitine pools beyond a single metabolite. This promiscuity partially explains why complete
    SBCAD loss-of-function has limited clinical consequences in most individuals.

    &#39;
  biological_processes:
  - preferred_term: fatty acid beta-oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:37309295
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: &#39;Deficiencies of these acyl-CoA dehydrogenase (ACAD) enzymes are considered biochemical abnormalities with limited
      or no clinical consequences.

      &#39;
    explanation: &#39;Expert consensus statement from 2023 JIMD paper characterizing SBCAD deficiency as largely a biochemical
      abnormality.

      &#39;
phenotypes:
- name: Developmental delay
  frequency: OCCASIONAL
  description: &#39;Motor and cognitive developmental delay is reported in a minority of symptomatic SBCADD patients. One of the
    earliest reported patients had severe motor developmental delay with muscle atrophy.

    &#39;
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:12837870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;One patient developed athetoid cerebral palsy, and another had severe motor developmental delay with muscle
      atrophy.

      &#39;
    explanation: &#39;Two of the earliest described patients showed motor developmental delay or cerebral palsy.

      &#39;
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure
      to thrive.

      &#39;
    explanation: &#39;Literature review confirms developmental delay as a recognized phenotype of symptomatic SBCADD.

      &#39;
- name: Seizures
  frequency: OCCASIONAL
  description: &#39;Seizures are reported in symptomatic SBCADD patients, occurring at clinical onset or developing during follow-up.
    Epilepsy may develop on longitudinal follow-up.

    &#39;
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure
      to thrive.

      &#39;
    explanation: &#39;Seizures listed as a recognized presenting feature of symptomatic SBCADD.

      &#39;
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;On longitudinal follow-up, epilepsy, developmental delay, microcephaly, and autism can develop.

      &#39;
    explanation: &#39;Epilepsy can develop on longitudinal follow-up in symptomatic cases.

      &#39;
- name: Muscular hypotonia
  frequency: OCCASIONAL
  description: &#39;Hypotonia is a recognized feature of symptomatic SBCADD, reported in both early-onset presentations and in
    newborn-screening-identified patients.

    &#39;
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:12837870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Except for 1 patient who developed mild muscle hypotonia, all patients remain asymptomatic at ages ranging from
      3 to 14 months of age.

      &#39;
    explanation: &#39;Reports mild muscle hypotonia in one of the newborn-screening- identified Hmong patients.

      &#39;
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure
      to thrive.

      &#39;
    explanation: &#39;Hypotonia listed among presenting features in the literature review.

      &#39;
- name: Failure to thrive
  frequency: OCCASIONAL
  description: &#39;Failure to thrive is reported in symptomatic SBCADD patients, likely related to feeding difficulties and recurrent
    metabolic instability.

    &#39;
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure
      to thrive.

      &#39;
    explanation: &#39;Failure to thrive listed among presenting features in the literature review of 162 patients.

      &#39;
- name: Microcephaly
  frequency: VERY_RARE
  description: &#39;Microcephaly has been reported in a minority of SBCADD patients on longitudinal follow-up.

    &#39;
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;On longitudinal follow-up, epilepsy, developmental delay, microcephaly, and autism can develop.

      &#39;
    explanation: &#39;Microcephaly listed as a feature that can develop on longitudinal follow-up.

      &#39;
- name: Autism
  frequency: VERY_RARE
  description: &#39;Autism spectrum disorder has been reported in a minority of SBCADD patients on longitudinal follow-up.

    &#39;
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;On longitudinal follow-up, epilepsy, developmental delay, microcephaly, and autism can develop.

      &#39;
    explanation: &#39;Autism listed among features that can develop on longitudinal follow-up in SBCADD.

      &#39;
- name: Dyskinetic cerebral palsy
  frequency: VERY_RARE
  description: &#39;Athetoid cerebral palsy was reported in one of the original patients described with SBCADD.

    &#39;
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: PMID:12837870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;One patient developed athetoid cerebral palsy, and another had severe motor developmental delay with muscle
      atrophy.

      &#39;
    explanation: &#39;Directly reports athetoid cerebral palsy in one of the first described SBCADD patients.

      &#39;
- name: Skeletal muscle atrophy
  frequency: VERY_RARE
  description: &#39;Muscle atrophy was reported in one of the original SBCADD patients, associated with severe motor developmental
    delay.

    &#39;
  phenotype_term:
    preferred_term: Skeletal muscle atrophy
    term:
      id: HP:0003202
      label: Skeletal muscle atrophy
  evidence:
  - reference: PMID:12837870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;One patient developed athetoid cerebral palsy, and another had severe motor developmental delay with muscle
      atrophy.

      &#39;
    explanation: &#39;Directly reports muscle atrophy in an early SBCADD patient.

      &#39;
- name: Elevated C5-acylcarnitine on newborn screening
  frequency: VERY_FREQUENT
  diagnostic: true
  description: &#39;Elevated C5-acylcarnitine (2-methylbutyrylcarnitine, isobaric with isovalerylcarnitine) on tandem mass spectrometry
    newborn screening is the primary ascertainment marker for SBCADD.

    &#39;
  phenotype_term:
    preferred_term: Elevated circulating acylcarnitine concentration
    term:
      id: HP:0045045
      label: Elevated circulating acylcarnitine concentration
- name: 2-Methylbutyrylglycinuria
  frequency: VERY_FREQUENT
  diagnostic: true
  description: &#39;Increased urinary excretion of 2-methylbutyrylglycine is the biochemical hallmark of SBCADD, detected by urine
    organic acid analysis.

    &#39;
  phenotype_term:
    preferred_term: Organic aciduria
    term:
      id: HP:0001992
      label: Organic aciduria
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Increased urinary excretion of 2-methylbutyrylglycine (2MBG) is the hallmark of SBCAD deficiency.

      &#39;
    explanation: &#39;Directly identifies elevated urinary 2-MBG as the hallmark of SBCADD.

      &#39;
  - reference: PMID:31555323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;All patients who underwent urinary organic acid analysis showed elevation of 2-methylburtyrylglycine in urine.

      &#39;
    explanation: &#39;Confirms universal 2-MBG elevation in confirmed SBCADD patients.

      &#39;
- name: Largely asymptomatic course
  frequency: VERY_FREQUENT
  description: &#39;The majority of individuals with SBCADD remain clinically asymptomatic. In a literature review of 162 patients,
    SBCADD was symptomatic in only about 10% of reported patients.

    &#39;
  notes: &#39;Many individuals are identified through newborn screening and remain well without treatment on long-term follow-up.

    &#39;
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Based on our experience and the literature review (162 patients), SBCAD deficiency is symptomatic in about 10%
      of reported patients.

      &#39;
    explanation: &#39;Quantifies the largely asymptomatic nature of SBCADD in the largest literature review.

      &#39;
  - reference: PMID:20547083
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Our patients have been well without treatment and call for careful follow-up studies to learn the true clinical
      impact of this disorder.

      &#39;
    explanation: &#39;Confirms asymptomatic status of non-Hmong patients identified by newborn screening.

      &#39;
biochemical:
- name: C5-acylcarnitine (2-methylbutyrylcarnitine)
  presence: INCREASED
  context: &#39;Elevated C5-acylcarnitine in blood is the primary newborn screening marker for SBCADD. C5 is isobaric with isovalerylcarnitine
    on standard tandem mass spectrometry, requiring second-tier testing to distinguish SBCADD from isovaleric acidemia.

    &#39;
- name: 2-Methylbutyrylglycine (2-MBG) in urine
  presence: INCREASED
  context: &#39;Elevated urinary 2-methylbutyrylglycine is the diagnostic hallmark of SBCADD. Detection of 2-MBG by urine organic
    acid analysis or acylglycine profiling confirms the diagnosis after elevated C5 is found on newborn screening.

    &#39;
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Increased urinary excretion of 2-methylbutyrylglycine (2MBG) is the hallmark of SBCAD deficiency.

      &#39;
    explanation: &#39;Confirms 2-MBG elevation as the hallmark in the 2019 literature review.

      &#39;
- name: 2-Ethylhydracrylic acid (2-EHA) in urine
  presence: INCREASED
  context: &#39;2-Ethylhydracrylic acid is a urinary organic acid marker of SBCADD, produced by increased flux through the R-pathway
    of isoleucine oxidation. The 2-EHA peak often exceeds the 2-MBG peak on organic acid analysis and may facilitate diagnosis.

    &#39;
  evidence:
  - reference: PMID:15615815
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;In multiple urine samples, organic acid analysis revealed a prominent 2-EHA peak usually exceeding the size
      of the 2-MBG peak.

      &#39;
    explanation: &#39;Demonstrates that 2-EHA is a prominent urinary marker in SBCADD, often exceeding 2-MBG levels.

      &#39;
  - reference: PMID:15615815
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Awareness of 2-ethylhydracrylic aciduria as a diagnostic marker could lead to increased detection of SBCADD
      and improved definition of its clinical phenotype.

      &#39;
    explanation: &#39;Supports diagnostic utility of 2-EHA for SBCADD detection.

      &#39;
- name: C3-carnitine (propionylcarnitine) in ACADSB knockout cells
  presence: DECREASED
  context: &#39;In cell models of SBCAD deficiency, C3-carnitine is substantially decreased, reflecting the broader impact of
    SBCAD on mitochondrial acyl-CoA handling beyond the direct isoleucine pathway metabolites. This is an in vitro observation
    and not a standard clinical biomarker.

    &#39;
  evidence:
  - reference: PMID:37309295
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: &#39;deletion of ACADSB in HEK-293 cells led to an equally strong decrease in C3-carnitine when compared to wild-type
      cells.

      &#39;
    explanation: &#39;ACADSB knockout in HEK-293 cells causes substantial C3-carnitine decrease, demonstrating broader metabolic
      impact.

      &#39;
genetic:
- name: ACADSB pathogenic variants
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:12837870
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#39;2-methylbutyryl-CoA dehydrogenase deficiency, also known as short/branched-chain acyl-CoA dehydrogenase (SBCAD)
        deficiency, is a recently described autosomal recessive disorder of L-isoleucine metabolism.

        &#39;
      explanation: &#39;Directly states autosomal recessive inheritance for SBCADD.

        &#39;
  variants:
  - name: c.1165A&gt;G (exon 10 skipping) - founder variant
    description: &#39;The c.1165A&gt;G variant in ACADSB causes skipping of exon 10 and is a founder mutation highly prevalent in
      the Hmong population and in several Chinese ethnic minority groups (Miao, Dong). Homozygosity for this variant is found
      at a frequency of approximately 1.3% in the Hmong population, with a carrier frequency of 21.8%.

      &#39;
    evidence:
    - reference: PMID:12837870
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#39;Molecular genetic analysis performed for 3 of these patients revealed that all are homozygous for an 1165A&gt;G
        mutation that causes skipping of exon 10 of the SBCAD gene.

        &#39;
      explanation: &#39;Identifies the c.1165A&gt;G founder mutation and its effect on exon 10 splicing.

        &#39;
  - name: Multiple non-Hmong ACADSB missense variants
    description: &#39;Multiple missense variants in ACADSB have been identified in non-Hmong patients through newborn screening.
      Expression studies show these variants lead to inactivation or instability of the mutant SBCAD enzymes. At least 15
      pathogenic variants are known in ACADSB.

      &#39;
    evidence:
    - reference: PMID:20547083
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: &#39;Escherichia coli expression studies revealed that the missense mutations identified lead to inactivation or
        instability of the mutant SBCAD enzymes.

        &#39;
      explanation: &#39;Confirms functional impact of non-Hmong ACADSB variants through in vitro expression studies.

        &#39;
  features: &#39;SBCADD is caused by biallelic pathogenic variants in ACADSB (chromosome 10q26.13, 11 exons), encoding short/branched-chain
    acyl-CoA dehydrogenase (SBCAD), a homotetrameric mitochondrial FAD-containing enzyme. The c.1165A&gt;G founder variant is
    dominant in the Hmong and certain Chinese ethnic minorities, while diverse missense and truncating variants are found
    in other populations. Genotype-phenotype correlations remain uncertain, as most homozygous individuals remain asymptomatic
    regardless of variant type.

    &#39;
  evidence:
  - reference: PMID:20547083
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Short/branched chain acyl-CoA dehydrogenase (SBCAD) deficiency, also known as 2-methylbutyryl-CoA dehydrogenase
      deficiency, is a recently described autosomal recessive disorder of isoleucine metabolism. Most patients reported thus
      far have originated from a founder mutation in the Hmong Chinese population.

      &#39;
    explanation: &#39;Confirms the genetic basis and founder mutation background of SBCADD.

      &#39;
  - reference: PMID:16950638
    supports: SUPPORT
    evidence_source: OTHER
    snippet: &#39;Confirmation of diagnosis is therefore advisable by specific enzyme assay and/or mutation analysis of the ACAT1
      (beta-KT), ACADSB (SBCAD) or HADH2 (MHBD) genes.

      &#39;
    explanation: &#39;Confirms ACADSB as the gene for molecular diagnosis of SBCADD.

      &#39;
treatments:
- name: Carnitine supplementation
  description: &#39;L-carnitine supplementation (typically 50-100 mg/kg/day) is used to support conjugation and excretion of accumulating
    acyl-CoA intermediates as acylcarnitine species. Carnitine supplementation is one of the most consistently recommended
    interventions in SBCADD management.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Carnitine supplementation and valproate avoidance appear to be indicated.

      &#39;
    explanation: &#39;Directly recommends carnitine supplementation as an indicated treatment for SBCADD.

      &#39;
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Longitudinal biochemical monitoring of the two patients while on treatment with carnitine (100 mg/kg/day) was
      provided.

      &#39;
    explanation: &#39;Reports specific carnitine dosing of 100 mg/kg/day with biochemical monitoring.

      &#39;
- name: Catabolic stress avoidance and emergency protocol
  description: &#39;Prevention of metabolic decompensation through avoidance of prolonged fasting, protein overload, and provision
    of an emergency protocol for management of intercurrent febrile illnesses and acute catabolic episodes.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Providing an emergency protocol for the management of acute catabolic episodes seems reasonable in asymptomatic
      patients with SBCAD deficiency.

      &#39;
    explanation: &#39;Directly supports emergency protocol provision for catabolic stress management.

      &#39;
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Catabolic situations can precipitate acute metabolic decompensation.

      &#39;
    explanation: &#39;Supports the rationale for catabolic stress avoidance.

      &#39;
- name: Dietary management
  description: &#39;Dietary intervention in SBCADD is controversial. Early-identified cases historically received low-protein
    diets with fasting avoidance, but the indication for disruptive dietary manipulations in asymptomatic newborn-screening-identified
    infants is questionable. Current practice favors maintaining a normal diet with vigilance during intercurrent illness
    rather than protein restriction.

    &#39;
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:12837870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Dietary treatment was initiated in the neonatal period. Except for 1 patient who developed mild muscle hypotonia,
      all patients remain asymptomatic at ages ranging from 3 to 14 months of age.

      &#39;
    explanation: &#39;Reports early dietary treatment in newborn-screening-identified Hmong patients with good short-term outcomes.

      &#39;
  - reference: PMID:12837870
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;The continued efficacy of long-term dietary therapy instituted presymptomatically remains to be established.

      &#39;
    explanation: &#39;Notes that long-term efficacy of presymptomatic dietary treatment is unproven.

      &#39;
- name: Valproate avoidance
  description: &#39;Valproate should be avoided in SBCADD patients because valproyl-CoA can serve as a substrate of SBCAD, and
    valproate administration may exacerbate the metabolic block.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Carnitine supplementation and valproate avoidance appear to be indicated.

      &#39;
    explanation: &#39;Directly recommends valproate avoidance as an indicated measure in SBCADD management.

      &#39;
- name: Newborn screening via tandem mass spectrometry
  description: &#39;SBCADD is detectable by expanded newborn screening using tandem mass spectrometry. Elevated C5-acylcarnitine
    triggers follow-up testing including urine organic acids and acylglycine analysis, followed by molecular confirmation
    of ACADSB variants.

    &#39;
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:12837870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;These cases suggest that SBCAD deficiency is another inborn error of metabolism detectable by newborn screening
      using tandem mass spectrometry.

      &#39;
    explanation: &#39;Establishes that SBCADD is detectable by tandem MS newborn screening.

      &#39;
- name: Genetic counseling
  description: &#39;Genetic counseling for affected families regarding autosomal recessive inheritance, carrier testing, recurrence
    risk (25%), and options for prenatal diagnosis. Particularly relevant in the Hmong community where the carrier frequency
    exceeds 20%.

    &#39;
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:12837870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;A sibling of the first patient is asymptomatic after prenatal diagnosis and early treatment.

      &#39;
    explanation: &#39;Demonstrates prenatal diagnosis has been applied in SBCADD families, supporting the role of genetic counseling.

      &#39;
- name: Longitudinal monitoring
  description: &#39;Long-term clinical and biochemical follow-up is recommended for all individuals with confirmed SBCADD, even
    those who are asymptomatic, to monitor for late-onset neurological or developmental complications and to assess the natural
    history of the condition.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:30730842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Longitudinal follow-up is recommended.

      &#39;
    explanation: &#39;Directly recommends longitudinal follow-up in SBCADD.

      &#39;
notes: &#39;SBCADD is a condition of uncertain clinical significance for most affected individuals. Expert consensus from 2023
  characterizes SBCAD deficiency as a biochemical abnormality with limited or no clinical consequences in most cases. However,
  the 2019 literature review cautions that considering SBCADD a non-disease in non-Hmong subjects appears unsafe, as catabolic
  stress can precipitate acute decompensation. The condition is particularly common in the Hmong population (carrier frequency
  ~22%) and in certain Chinese ethnic minorities (Miao, Dong) due to the founder c.1165A&gt;G variant. The role of treatment
  in SBCADD remains unclear pending further delineation of its clinical phenotype and pathogenicity.

  &#39;
references: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/2-Methylbutyryl-CoA_Dehydrogenase_Deficiency.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>